Advertisement
Advertisement
QGEN
QIAGEN N.V.
34.24
USDSponsored
+0.46
+1.36%
May 19, 15:59 UTC -4
Closed
After-Market
34.58
+0.34
+0.99%
QGEN Earnings Reports
Positive Surprise Ratio
QGEN beat 31 of 41 last estimates.
76%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$544.30M
/$0.61
Implied change from Q1 26 (Revenue/ EPS)
+10.63%
/+12.96%
Implied change from Q2 25 (Revenue/ EPS)
+2.02%
/-3.17%
QIAGEN N.V. earnings per share and revenue
On May 06, 2026, QGEN reported earnings of 0.54 USD per share (EPS) for Q1 26, missing the estimate of 0.55 USD, resulting in a -2.09% surprise. Revenue reached 492.00 million, compared to an expected 507.20 million, with a -3.00% difference. The market reacted with a -2.70% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of 0.61 USD, with revenue projected to reach 544.30 million USD, implying an increase of 12.96% EPS, and increase of 10.63% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Satellos Bioscience Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.61
Actual
-$0.53
Surprise
+13.58%
Rani Therapeutics Holdings, Inc. Class A Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.04
Surprise
+12.85%
aTyr Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.11
Surprise
+21.60%
Citius Oncology, Inc. Common Stock
Report Date
May 15, 2026 For Q2 26
Estimate
-$0.01
Actual
-$1.43
Surprise
-13919.61%
Instil Bio, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.59
Actual
-$0.62
Surprise
-4.04%
Annovis Bio, Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.40
Actual
-$0.63
Surprise
-56.37%
CervoMed Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.79
Actual
-$0.86
Surprise
-8.09%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
Cocrystal Pharma, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
FAQ
What were QIAGEN N.V.'s earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, QIAGEN N.V. reported EPS of $0.54, missing estimates by -2.09%, and revenue of $492.00M, -3% below expectations.
How did the market react to QIAGEN N.V.'s Q1 2026 earnings?
The stock price moved down -2.7%, changed from $34.44 before the earnings release to $33.51 the day after.
When is QIAGEN N.V. expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for QIAGEN N.V.'s next earnings report?
Based on 12
analysts, QIAGEN N.V. is expected to report EPS of $0.61 and revenue of $544.30M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement